PROPANC BIOPHARMA INC (PPCB) Stock News

USA - NASDAQ:PPCB - US74346N7012 - Common Stock

1.52 USD

+0.04 (+2.7%)

Last: 10/24/2025, 8:00:01 PM

1.4807 USD

-0.04 (-2.59%)

After Hours: 10/24/2025, 8:00:01 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

PPCB Latest News, Press Relases and Analysis

All

Press Releases

11 days ago - By: Propanc Biopharma, Inc.

CORRECTION: Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital

11 days ago - By: Propanc Biopharma, Inc.

CORRECTION: Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital

12 days ago - By: Propanc Biopharma, Inc.

Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital

12 days ago - By: Propanc Biopharma, Inc.

Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital

20 days ago - By: Propanc Biopharma, Inc.

Propanc Reports End of Fiscal Year Highlights and Outlines Therapeutic Development & $100M+ Digital Asset Treasury Strategy

20 days ago - By: Propanc Biopharma, Inc.

Propanc Reports End of Fiscal Year Highlights and Outlines Therapeutic Development & $100M+ Digital Asset Treasury Strategy

a month ago - By: Propanc Biopharma, Inc.

Propanc Biopharma Receives Certificate of Grant for “Proenzyme Composition” Patent from US Patent & Trademark Office

a month ago - By: Propanc Biopharma, Inc.

Propanc Biopharma Receives Certificate of Grant for “Proenzyme Composition” Patent from US Patent & Trademark Office

2 months ago - By: Stocktwits

News Image

Why Propanc stock Is Tumbling In Premarket Today

2 months ago - By: Benzinga - Mentions: MTNB TPIC RSKD VTAK ...

US Stocks Mixed; Riskified Shares Dip After Q2 Results

2 months ago - By: Benzinga - Mentions: BRKR SLRX LUNG HOTH ...

12 Health Care Stocks Moving In Tuesday's After-Market Session

2 months ago - By: Propanc Biopharma, Inc.

Propanc Biopharma Announces Plan to Acquire $100 Million of Ethereum

2 months ago - By: Propanc Biopharma, Inc.

Propanc Biopharma Announces Plan to Acquire $100 Million of Ethereum

2 months ago - By: ACCESS Newswire

D. Boral Capital Acted as Lead Bookrunner to Propanc Biopharma, Inc. (Nasdaq:PPCB) in Connection with its $4,000,000 Uplisting

2 months ago - By: Propanc Biopharma, Inc.

Propanc Biopharma Provides Shareholder Update

2 months ago - By: Propanc Biopharma, Inc.

Propanc Biopharma Provides Shareholder Update

2 months ago - By: Propanc Biopharma, Inc.

Propanc Biopharma Announces Closing of Public Offering and Uplisting to NASDAQ

2 months ago - By: Propanc Biopharma, Inc.

Propanc Biopharma Announces Closing of Public Offering and Uplisting to NASDAQ

2 months ago - By: Propanc Biopharma, Inc.

Propanc Biopharma Announces Nasdaq Uplisting and Pricing of $4 Million Public Offering

2 months ago - By: Propanc Biopharma, Inc.

Propanc Biopharma Announces Nasdaq Uplisting and Pricing of $4 Million Public Offering

a year ago - By: Propanc Biopharma, Inc. - Mentions: OTC

Propanc Biopharma’s Peer Reviewed Articles for Proenzymes Cancer Treatment Generates “Unprecedented” Interest

a year ago - By: Propanc Biopharma, Inc. - Mentions: OTC

Propanc Biopharma Receives Notice of Allowance for “Proenzyme Composition” Patent in North America

a year ago - By: Propanc Biopharma, Inc. - Mentions: OTC

Propanc Biopharma’s CSO Predicts PRP Could Solve Problem That Impacts Response Rate of Immune Checkpoint Inhibitors Treating Solid Tumors

a year ago - By: Propanc Biopharma, Inc. - Mentions: OTC

Propanc Biopharma Receives Certificate of Grant for “Proenzymes Composition” Patent from Japanese Patent Office

2 years ago - By: Propanc Biopharma, Inc. - Mentions: OTC

Propanc Biopharma Receives Certificate of Grant for “Composition of Proenzymes for Cancer Treatment” Patent from European Patent Office